EU projects

Eureka Eurostars

MNM implements project: PARPiNDx, a novel genomic based classifier for prediction of PARP inhibitor response in ovarian cancer.

The project has received funding from the Eurostars Joint Programme with co-funding from the European Union Horizon 2020 Research and Innovation Programme and The National Centre for Research and Development.

Acronym: PARPiNDx

Project goal: The aim of the project is to create an AI-powered diagnostic tool - PARPiNDx, designed to improve ovarian cancer patient classification, increasing their chances for successful clinical outcomes. PARPiNDx utilizes the most advanced genomic sequencing technology, and an AI approach to select patients, who will respond to PARP inhibitors.

Total value: EURO 698,679.00

Financial support: EURO 271,557.10

Project number: 653

Eureka website:

NCRD website:

Go to brand

MNM implements project no. POIR.03.03.03-30-0191/20 co-financed by the European Regional Development Fund under the Intelligent Development Operational Program 2014-2020.

Measure 3.3: Support for the promotion and internationalization of innovative enterprises

Sub-measure 3.3.3: Support for SMEs in the promotion of product brands - Go to Brand

Project title: Development of the export activity of MNM through promotional activities of the brand on foreign markets

Project goal: The aim of the project is to popularize and sell genomic profiling services on foreign markets, and identify mutations responsible for the emergence of rare diseases and biobank cancer tissues.

Total value: PLN 308,200.00

Project co-financing value from the EU: PLN 261,970.00

Project number: POIR.03.03.03-30-0191/20-00